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Abstract
Background: It has been debated whether point-of care 
(POC) glycated hemoglobin (HbA1c) measurements 
methods can be used for diagnosing persons with diabe-
tes mellitus. The aim of this study was to evaluate the ana-
lytical performance of the POC Afinion HbA1c system in 
the hands of the users, and to investigate which predictors 
that were associated with good participant performance.
Methods: External quality assurance (EQA) data from 
seven surveys in 2017–2018  with a total of 5809 Afinion 
participants from a POC total quality system in Norway 
were included in this study (response rate 90%). The 
control materials were freshly drawn pooled EDTA whole 
blood. Each participant was evaluated against the ana-
lytical performance specification of ±6% from the target 
value, while the Afinion system was evaluated against the 
pooled within-laboratory CV <2%, the between-laboratory 
CV <3.5%, and bias <0.3%HbA1c. Logistic regression anal-
yses were used to investigate which factors were associ-
ated with good participant performance.
Results: The participant pass rates for each survey varied 
from 98.2% to 99.7%. The pooled within-laboratory 
CV varied from 1.3% to 1.5%, the between-laboratory 
CV varied from 1.5% to 2.1%, and bias varied between 
−0.17 and −0.01 %HbA1c in all surveys. Reagent lot was 
the only independent factor to predict good participant 
performance.
Conclusions: Afinion HbA1c fulfilled the analytical 
 performance specifications and is robust in the hands of 
the users. It can therefore be used both in diagnosing and 
monitoring persons with diabetes mellitus, given that the 
instrument is monitored by an EQA system.
Keywords: analytical performance specifications; diabe-
tes mellitus; external quality assurance; glycated hemo-
globin; point-of-care testing.
Introduction
The level of glycated hemoglobin (HbA1c) plays a criti-
cal role in diagnosing and monitoring diabetes mellitus. 
Acceptable precision and trueness of the HbA1c meas-
urement methods are therefore essential. Point-of-care 
testing (POCT) is widely used for HbA1c monitoring. It 
reduces the turnaround times and may increase the effi-
cacy of the service provided to patients [1, 2]. When used 
both for diagnostic and monitoring purposes, the POCT 
HbA1c measurement methods should meet the same ana-
lytical performance specifications as central laboratories.
External quality assurance (EQA) is a tool for the 
individual laboratories to assess their own performance, 
compare results with others or, if a commutable material 
is used, compare results with a target value set by a ref-
erence measurement procedure. For POCT measurement 
methods, it is important to evaluate performance in the 
hands of the intended users. Results from EQA can reflect 
real-life performance and is therefore an excellent tool to 
evaluate not just the individual participants’ performance, 
but also the field analytical quality of POCT methods [3].
Noklus is a nonprofit organization and has offered 
EQA schemes for POCT since 1992 [4]. However, EQA is 
only one part of the total quality improvement system 
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offered by Noklus; the organization offer participants 
guidance and education through site visits, telephone 
consultations and courses, gives advice about what 
instruments to buy, and provides EQA schemes for most 
of the analytes used in primary healthcare. Participa-
tion in Noklus is not mandatory; nevertheless, 99% of all 
general practitioner (GP) offices and 96% of all nursing 
homes in Norway participate, in addition to other par-
ticipants in primary care (home care, prisons, oil plat-
forms, etc.), and Norwegian hospitals; altogether more 
than 3100 participants.
For HbA1c, Noklus has about 1500 participants from 
both hospitals and primary healthcare. A commut-
able EDTA whole blood material is circulated and target 
values are set by reference measurement methods, 
meaning that the trueness of all HbA1c methods on the 
Norwegian market is evaluated and monitored. Because 
the participants analyze the samples in duplicate, we 
are also able to calculate and monitor the precision of 
the measurement methods. In addition, we always ask 
for the reagent lot number used in each EQA scheme for 
all components, meaning that the lot-to-lot variation is 
possible to monitor. Such information has been reported 
to be critical for the correct interpretation of the partici-
pant performance [5]. Furthermore, each time we ask for 
several participant performance characteristics, meaning 
that we can evaluate which of these factors predict good 
performance [6].
The aim of this study was to use EQA data to evalu-
ate the field analytical performance of the Afinion HbA1c 
system in general practice offices against predefined 
performance specifications. In addition, we investi-
gated which predictors that were associated with good 
 participant performance.
Materials and methods
EQA control samples and number of participants
Noklus provides four EQA HbA1c surveys per year to both hospital lab-
oratories and to POCT users. Results from the seven surveys in 2017–
2018 were included in this study. The last survey in 2018 (4-2018) was 
not included because in Norway, the HbA1c units were changed from 
% (NGSP unites) to mmol/mol (IFCC SI units) in the period between 
survey 3-2018 and 4-2018. Results from surveys before 2017  were 
not included because the manufacturer of Afinion™ (Abbott, USA) 
released an improved HbA1c assay software for the Afinion analyzer 
from 2017. The total number of participants in the seven Noklus EQA 
surveys is shown in Table 1 together with the number of participants 
using the Afinion system (Alere Afinion AS100 Analyzer, Afinion 2). 
The Afinion participants were from primary health care only, mainly 
GP offices (95%).
For each EQA survey, the participants received two samples of 
500 μL in two levels. The material was freshly drawn pooled EDTA 
whole blood from eight to 10 persons with and without diabetes. The 
samples were distributed by ordinary post mail. The participants 
were instructed to store the samples at 4 °C, to make sure that the 
samples reached room temperature before analysis, to analyze the 
samples in duplicate, preferably on two consecutive days, and to 
report the results within 1 week. For more details about the Noklus 
HbA1c EQA scheme, see Solvik et al. [7].
Participant characteristics
For every EQA survey, independent of the analyte in question, Noklus 
always asks the participant to report information about which instru-
ment and reagent lot number they used, the profession of the opera-
tor (in order of most to least skilled in laboratory work: biomedical 
laboratory scientist, medical secretary, nurse, GP/other), the number 
of patient samples performed per week (1–10, 11–15, 16–20, >20) and 
the frequency of running internal quality control (IQC) (daily/weekly, 
monthly, when opening a new reagent kit, never), in addition to the 
test result. These additional variables were used in logistic regression 
Table 1: Number of participants in the Noklus’ EQA surveys for HbA1c, and the performance of the participants using Afinion.
EQA survey Totala Afinion participants
n n Response rate Good/good n (%) Poor ×1 n (%) Other n (%)
1-2017 1486 819 89.3 715 (97.8) 16 (2.2) 0 (0.0)
2-2017 1487 823 89.4 726 (98.6) 7 (1.0) 3 (0.4)
3-2017 1472 818 90.2 733 (99.3) 4 (0.5) 1 (0.1)
4-2017 1476 821 91.4 742 (98.9) 5 (0.7) 3 (0.4)
1-2018 1482 827 91.1 741 (98.4) 12 (1.6) 0 (0.0)
2-2018 1478 849 90.7 764 (99.2) 5 (0.6) 1 (0.1)
3-2018 1480 852 89.1 748 (98.6) 10 (1.3) 1 (0.1)
Sum 10,361 5809 90.2 5169 (98.7) 59 (1.1) 9 (0.2)
aTotal number of participants both from primary healthcare and hospital laboratories. Good/Good, good performance on both control 
sample 1 and 2; Poor ×1; poor performance on at least one of the two control samples; Other, other combinations (e.g. good/no answer).
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models to investigate which were associated with good participant 
performance.
Stability and homogeneity
For each EQA survey the stability of the control material was exam-
ined according to ISO 13528 [8]. Examination of the homogeneity of 
this control material is considered irrelevant and was not performed. 
Examination of stability was performed at the Department of Medi-
cal Biochemistry and Pharmacology (Haukeland University Hospital, 
Bergen, Norway) in the following way: Two cryovials at each HbA1c 
level were first stored for 1 day at room temperature, then one vial 
from each level was frozen and the other vials were stored at 4 °C for 
6 days and then frozen. All frozen vials were thawed and analyzed 
at the same time on the Variant II HPLC (Bio-Rad Laboratories) in 
six replicates. The material fulfilled the stability requirements [8] in 
all EQA surveys. In addition to this stability testing, the day-to-day 
stability using the participant’s reported results was evaluated and 
accepted in each survey.
Target values
The target value for each EQA sample was assigned by the European 
Reference Laboratory for Glycohemoglobin (ERL) (Winterswijk, The 
Netherlands), by using three IFCC secondary reference measure-
ment procedures; (1) HA8180V, ionic exchange HPLC (Menarini), (2) 
Hb9210, affinity chromatography HPLC (Trinity Biotech), and (3) Cap-
illary 2 FP, capillary electrophoresis (Sebia). The results were given in 
both %HbA1c (DCCT/NGSP units) and mmol/mol HbA1c (IFCC units). 
In this study, the DCCT/NGSP units were used, which was in line with 
common practice in Norway before the last quartile of 2018. The tar-
get value was the mean of duplicate measurements from the three 
mentioned reference methods. The DCCT/NGSP values were derived 
from IFCC values using the master equation [9].
Performance specifications
The participant performance specification of ±6% recommended 
by the College of American Pathologists (CAP) [10] was used in this 
study. This specification is based on single measurements. However, 
in the Noklus EQA schemes the mean of duplicate measurements is 
used instead of single measurements. The participant performance 
in this report was categorized as “good” if the mean of the duplicate 
measurements was within 6% of the target value, and “poor” if the 
result was outside these limits.
The performance of the measurement methods was evaluated 
against the method performance specifications of a within-laboratory 
CV of <2% and a between-laboratory CV of <3.5% as recommended by 
the National Academy of Clinical Biochemistry (NACB) [11] for meth-
ods used for diagnosis of diabetes. The specification for between-lab-
oratory CV is also used by CAP [10]. In addition, the mean systematic 
deviation from the target value (bias) for the Afinion system was eval-
uated against the specification of bias <0.3 %HbA1c used by CAP [10].
Statistics
Before calculating the within- and between-laboratory analytical 
imprecision, outliers were excluded (values outside mean ± 3 SD). 
The number (percent) of outliers varied between 4 (0.5%) and 13 
(1.8%) in the different surveys.
The participants analyzed each EQA sample in duplicate, usu-
ally on two different days. The difference between these duplicate 
measurements was used to estimate the pooled within-laboratory 
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where x̅i is the mean of duplicate measurements for each participant, 
x̅mean dup is the mean of the duplicate measurements for all partici-
pants, n is the number of participants, and median is the median of 
all duplicate means.
The between-laboratory variation based on single measure-
ments was calculated for each EQA survey using the formula:
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Logistic regression analyses were used to investigate which 
factors were associated with good participant performance. The 
outcome (dependent variable) was the participant performance 
with the two categories “good” and “poor” performance. Good 
performance was defined as results within the performance speci-
fication on both controls (sample 1 and 2) in an EQA survey (good/
good). Poor performance was defined as results outside the per-
formance specifications on at least one of the two control samples 
(poor/good, good/poor and poor/poor). The categorical predic-
tors (independent variables) were the above-mentioned variables 
describing the participants and the reagent lot numbers used. The 
logistic regression analysis was performed for each EQA survey sep-
arately and for all seven surveys combined. In the latter analysis, 
kit reagent lot numbers used by less than 20 participants and miss-
ing lot numbers were grouped in a separate category. The kit rea-
gent lot number with the highest number of participants was used 
as reference category. p-Values <0.05 were considered statistically 
significant. IBM SPSS Statistics 25.0 was used to perform the logistic 
regression analyses.
Student’s t-test was used to evaluate differences between kit rea-
gent lot numbers in each survey, and p-values <0.01 were considered 
statistically significant. The median value for lot numbers used by 
five or more participants were included in the evaluation.
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Results
Participant performance
The response rate was about 90% in all seven EQA surveys 
(Table 1). The overall pass rates for the Afinion users, i.e. 
the percentage of participants within the performance 
specifications of ±6%, varied from 98.2% to 99.7% for 
each control sample in each EQA survey, and from 97.8% 
to 99.3% when the two control samples were combined 
(both passing) in the different EQA surveys (Table 1). The 
distribution of participant results in relation to the per-
formance specifications is illustrated in Youden plots for 
each EQA survey in Supplementary Figure 1.
Factors that predicted good participant 
performance
Predictors that were associated with good participant 
performance for the Afinion users were different in the 
different surveys, meaning that no predictor was con-
stantly associated with good participant performance 
more than once when performing logistic regression 
analysis for each EQA survey separately. Several groups 
had no participants with poor performance in each EQA 
survey, meaning that the odds ratios could not be calcu-
lated (zero cells).
When pooling results from all seven EQA surveys, 
the factors “Frequency of internal QC” and “Kit reagent 
lot number” were associated with good performance 
(Table  2). Performing internal QC monthly was associ-
ated with better performance than using daily/weekly 
internal QC. Five lot numbers were associated with poorer 
results than the other reagent lots (odds ratio lower than 1) 
(Table 2). Five other lot numbers had no participants with 
poor performance (Table 2).
Measurement method performance
All HbA1c measurement methods used in primary health-
care and hospitals in Norway fulfilled the recommended 
requirements for bias for all samples in all EQA surveys 
(Figure 1). The pooled within-laboratory CV was less than 
2% for all measurement methods, except for the POCT 
Quo-Test A1c which had CV > 2% in nine of 14 control 
samples (Figure 1).
For the Afinion system, the pooled within-laboratory 
CV varied from 1.3% to 1.5%, the between-laboratory CV 
varied from 1.5% to 2.1%, and the systematic deviation 
from the reference target value (bias) varied between −0.17 
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Figure 1: Pooled within-laboratory CV and mean systematic deviation from the target value (bias) in relation to the recommended 
performance specifications (gray lines) for the most commonly used HbA1c measurement methods in primary care and hospitals in Norway.
Results from seven HbA1c EQA surveys in 2017–2018 (14 samples in total). n = average number of participants in the surveys. Afinion 
(n = 724): Alere Afinion AS100 Analyzer/Afinion 2; DCA (n = 459 primary care, n = 25 hospitals): DCA 2000/2000 + /Vantage; Architect (n = 6): 
Architect c4000/c8000/ci8200 (Tina-quant); BioRad/Variant (n = 9): BioRad D10/D100/Variant II Turbo (HPLC); Cobas (n = 20): Cobas c501/
c502, Cobas Integra 400/400 Plus/800 (Tina-quant); Tosoh (n = 13): Tosoh G7/G8/G11 (HPLC); Quo-Test A1c (n = 12).
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Afinion reagent lot-to-lot variation
A total of 28 different kit reagent lot numbers were used 
by n ≥ 5 Afinion participants in the seven EQA surveys 
(Supplementary Tables 1–7). Statistically significant 
differences between some of the reagent lots were 
detected in all surveys. However, the maximum devia-
tion between two lot numbers in each survey was less 
than 0.2 %HbA1c. Statistically significant differences 
from the target value were found for 58% of the reagent 
Table 2: Logistic regression analysis for all seven EQA surveys combined for Afinion HbA1c.
Predictors   Odds ratio (95% CI)
Profession of the operator
 Medical secretary (n = 4158)   1 (ref)
 Biomedical laboratory scientist (n = 268)   3.9 (0.5–29)
 Nurse (n = 602)   1.4 (0.5–3.6)
 GP and others (n = 121)   0.8 (0.2–3.4)
 No answer (n = 79)   0.3 (0.1–1.2)
Number of HbA1c analyses performed per week
 1–10 (n = 1744)   1 (ref)
 11–15 (n = 854)   0.8 (0.4–1.9)
 16–20 (n = 677)   0.8 (0.3–1.7)
  > 20 (n = 1888)   1.2 (0.6–2.4)
 No answer (n = 65)   0.3 (0.1–1.2)
Frequency of internal QC  
 Daily/weekly (n = 2905)   1 (ref)
 Monthly (n = 1174)   2.7 (1.1–6.6)a
 When opening a new reagent kit (n = 382)   1.2 (0.4–3.1)
 Never (n = 181)   0.7 (0.2–2.5)
 No answer (n = 586)   1.3 (0.6–3.1)
Kit reagent lot number   Lot code  Exp. date 
10193607 (n = 666)   21  10.2019  1 (ref)
10196709 (n = 155)   27  05.2020  0.8 (0.1–7.4)
10195679 (n = 251)   26  03.2020  0.4 (0.1–1.8)
10195436 (n = 70)   25  02.2020  NPPb
10195320 (n = 134)   24  02.2020  0.6 (0.1–5.7)
10194835 (n = 232)   23  01.2020  0.3 (0.1–1.2)
10194033 (n = 221)   22  11.2019  0.3 (0.1–1.7)
10190990 (n = 131)   20  09.2019  0.1 (0.03–0.5)a
10190590 (n = 431)   19  08.2019  0.4 (0.1–1.6)
10190252 (n = 397)   18  06.2019  0.6 (0.1–3.1)
10189769 (n = 29)   17  06.2019  NPPb
10189349 (n = 389)   16  05.2019  0.6 (0.1–3.0)
10188585 (n = 116)   15  03.2019  0.5 (0.1–4.9)
10188397 (n = 149)   14  03.2019  NPPb
10187455 (n = 29)   13  02.2019  NPPb
10186921 (n = 198)   12  12.2018  0.4 (0.1–2.6)
10186147 (n = 380)   11  11.2018  1.6 (0.2–16)
10185926 (n = 124)   10  11.2018  0.6 (0.1–5.4)
10185511 (n = 319)   9  10.2018  0.2 (0.6–0.9)a
10184794 (n = 34)   8  09.2018  NPPb
10184364 (n = 145)   7  07.2018  0.2 (0.04–0.8)a
10183704 (n = 36)   6  07.2018  0.03 (0.01–0.12)a
10183343 (n = 68)   5  06.2018  0.3 (0.03–3.0)
10182328 (n = 81)   4  03.2018  0.3 (0.03–3.2)
10179727 (n = 22)   2  09.2017  0.02 (0.004–0.11)a
No answer/n < 20 (n = 220)c       0.5 (0.1–3.2)
aOdds ratio different from 1, p < 0.05. bNPP, no poor performance. cLot number not reported (no answer), or lot numbers used by less than 20 
participants. Odds ratio (95% CI) for different predictors of good participant performance.
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lots, but all lots were within the bias specification of 0.3 
%HbA1c (Figures 2 and 3); the maximum deviation for one 
lot was 0.32 %HbA1c (lot code 6, lot number 10183704, 
control sample 2, 1-2017) (Figure 2).
When a lot number was used in several EQA surveys 
(e.g. lot codes 4 and 9  which represent lot numbers 
10185511 and 10182328, respectively), these lots had 
approximately the same deviation from the target value in 
all surveys (Figures 2 and 3).
Discussion
In this study we evaluated the analytical performance of 
POC HbA1c measurement methods used in primary health 
care in Norway, with special emphasis on the performance 
of the Afinion. It is currently debated whether POC HbA1c 
instruments have the sufficient analytical quality for diag-
nosis and management of patients with diabetes mellitus 
[11]. In a laboratory study, it has been shown that some 
of the POC measurement methods fulfilled the criteria for 
this purpose [12]. It is, however, also important to examine 
the quality of such instruments in “real life”. In this field 
study, we found that the Afinion measurement system 
had similar analytical quality as the hospital laboratory 
measurement methods and that they fulfilled the analyti-
cal performance specifications for bias and imprecision 
in the hands of the users. This confirms the findings in a 
previous paper [7].
Each participant in the Noklus EQA scheme for HbA1c 
was evaluated against the performance specification of 
total allowable deviation ±6% [10]. The overall pass rate 
for Afinion users was more than 98%, meaning that the 
participant performance was very good. The fact that 
the Afinion users participate in the Noklus total quality 
improvement system may have affected the quality in a 
positive way. It has been shown that participating in a 
quality management system with support from labora-
tory medicine professionals, will improve the quality of 
the POCT results [6, 13]. It might be argued that the high 
pass rate is because only the “good participants” report 
EQA results. However, as 99% of GP offices participate 
in Noklus, the response rate was about 90% in all seven 
surveys, and the non-responders were random (no con-
sistency), the results can be considered reliable.
Many factors can influence the quality of POC results 
[6]. In our study, we investigated which independent 
factors predict good analytical performance of Afinion 
HbA1c measurements. When pooling results from all seven 
surveys, the factor “reagent lot number” was associated 
with good participant performance (Table 2). The finding 
that performing internal QC monthly was associated with 
better performance than using daily/weekly QC should 
be interpreted with care as it is of borderline statistical 
significance and could be a random finding. Factors like 
profession of the operator and the number of HbA1c analy-
ses performed per week were not shown to influence the 
measurement quality. From the reagent lot evaluation 
in this study it seems like the newer lots are better than 
the old. Four out of the five lots that were associated with 
poorer results (Table 2) were used in the beginning of 2017, 
and from the third survey in 2018 only “good” lots were on 
the market. This indicates that the quality has improved 
Table 3: The within and between-laboratory CV and bias for the Afinion HbA1c for each control sample in each EQA survey.
EQA 
survey
  Sample  Target value 
(%HbA1c)






1-2017  1  5.96  715  −0.06  1.3 (1.24, 1.37)  1.8 (1.76, 1.95)
  2  7.07  712  −0.17  1.3 (1.22, 1.35)  1.8 (1.75, 1.94)
2-2017  1  5.52  707  −0.02  1.4 (1.34, 1.49)  1.8 (1.71, 1.90)
  2  6.22  703  −0.07  1.4 (1.33, 1.48)  1.9 (1.79, 1.99)
3-2017  1  5.25  720  −0.05  1.5 (1.46, 1.61)  2.0 (1.92, 2.13)
  2  6.44  714  −0.04  1.4 (1.32, 1.47)  1.9 (1.79, 1.98)
4-2017  1  6.12  729  −0.07  1.3 (1.22, 1.35)  1.8 (1.67, 1.85)
  2  6.98  723  −0.08  1.2 (1.09, 1.21)  1.7 (1.67, 1.85)
1-2018  1  5.01  729  −0.06  1.5 (1.45, 1.60)  1.8 (1.76, 1.95)
  2  6.24  726  −0.14  1.3 (1.24, 1.37)  1.8 (1.68, 1.86)
2-2018  1  5.48  749  −0.08  1.4 (1.30, 1.44)  2.0 (1.86, 2.06)
  2  7.72  744  −0.07  1.1 (1.06, 1.17)  1.5 (1.45, 1.60)
3-2018  1  5.00  734  −0.05  1.5 (1.39, 1.54)  2.1 (1.98, 2.19)
  2  6.76  731  −0.01  1.3 (1.22, 1.35)  1.7 (1.59, 1.76)
aAfter exclusion of outliers. CI, confidence interval.
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over time. This is also reported in a recent study from 
Sweden in which they show that the analytical quality of 
Afinion has increased over the years, now showing equal 
quality to hospital measurement methods [14].
In our study, we evaluated the bias and imprecision of 
different HbA1c measurement methods commonly used by 
hospital laboratories and primary health care in Norway. 
All methods, except the POCT Quo-Test A1c, fulfilled the 
6.40
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Figure 2: Median HbA1c values with 99% CI for each Afinion kit reagent lot number for control sample 1 and 2 in the 2017 EQA surveys.
The horizontal solid lines represent the target value, the dotted lines the performance specification for acceptable bias (±0.3 %HbA1c).
Stavelin et al.: Performance of Afinion HbA1c measurements in general practice      595
analytical performance specifications. Even if the HbA1c 
measurement methods fulfilled the specification for 
imprecision, it is important to notice that the CVs in this 
study are an expression of the pooled within-laboratory 
variation and not an expression of the imprecision in each 
laboratory. This means that even if a HbA1c measurement 
method has a CV below the criteria, some laboratories 
with this method can have larger CVs. Also, EQA results 
do not consider the uncertainty caused by pre-analytical 
factors, like, for example, blood sampling. In our study, 
the pooled within-laboratory CV for Afinion varied from 
1.3% to 1.5% in each survey, while in a single center study 
with one reagent lot only, the Afinion system achieved an 
imprecision CV <1.2% [12]. The CAP 2018 results showed 
that the Afinion had a bias between −0.18 and 0.05 %HbA1c 
in the different surveys (15 samples in total) [10] which is 
in line with our results (Table 3). The European HbA1c Trial 
showed a bias of −0.06% HbA1c and a between-laboratory 
CV of 2.2% for the Afinion system [15], which are in line 
with the findings in our study.
In conclusion, the Afinion HbA1c has an analytical 
quality that fulfills the performance specifications and is 
robust in the hands of the users. Therefore, it can be used 
in diagnosing and monitoring patients with diabetes, given 
that the instruments are monitored by an EQA system and 
that the operators participate in a total quality system for 
POCT. In the present study, reagent lot was an independent 
factor to predict good participant performance. Even if the 
Afinion reagent lot-to-lot variation was low, it is important 
to continue monitoring lots in EQA schemes in the future [5].
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